Tests tezepelumab in people with chronic obstructive pulmonary disease
Tests whether tezepelumab reduces airway inflammation in adults with COPD.
Plain-language title generated from the registry record
Registry title: Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of Tezepelumab
Key facts
- Where
- Copenhagen, DenmarkSee the site
- Phase
- Phase 2
Where in Denmark
- Respiratory Research unit, Bispebjerg HospitalCopenhagen, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Hovedstaden
- Trial code
- NCT05507242EU 2024-511730-12-00
- Record updated
- 2 February 2026
- Original description
To evaluate the effect of tezepelumab on eosinophilic bronchial mucosal tissue inflammation.Read full original descriptionShow less
Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of Tezepelumab
To evaluate the effect of tezepelumab on eosinophilic bronchial mucosal tissue inflammation.
Inclusion: Subjects with COPD on LABA+LAMA±ICS with ≥ 1 exacerbation the past 12 months; Postbronchodilator FEV1 ≥ 30% predicted (and ≥ 1.0L) and < 80% predicted; Age 40 years or older.
Exclusion: Exacerbation requiring oral corticosteroids or antibiotics (any dose for more than 3 days) 4 weeks prior to Visit 1 or during the run-in period; Any use of home oxygen therapy; Lung volume reduction surgery for COPD.